R&D The conflict in the Middle East is exposing dangerous prepar... If the conflict persists, the risk of widespread medicine shortages becomes increasingly real.
R&D LSX2026: Endogenous tissue restoration in vascular disease –... Paulo Neves, CMO of Xeltis, discusses transformative implants that enable the natural creation of living and long-lasting vessels.
R&D Neuroplasticity modulators as innovative potential disease-m... In September last year, we reported Servier had advanced its emerging neurology pipeline into the clinical trials stage by licensing a drug for the rare genetic disorder Fragile X syndrome
R&D 3 big unanswered questions about psychedelics When it comes to psychedelics in the mental health space, there are still some important foundational questions lacking settled answers.
R&D Sponsored The future of cardiometabolic trials: From obesity to outcom... Gain practical insight into how leading experts are designing the next generation of cardiometabolic trials in an upcoming webinar from hVIVO
R&D Parkinson’s disease: Transitioning from symptom control to d... The Parkinson's disease field is increasingly moving toward biologically defined disease frameworks using molecular biomarkers.
Oncology ASCO 2026: All about DNA damage response, with Luke Piggot Luke Piggot, a principal scientist at Debiopharm, shares some recent data and news about the company's work in DNA damage repair inhibitors.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
